{"id":{"repo_id":"marshall","oai_identifier":"oai:mds.marshall.edu:etd-2773"},"canonical_url":"https://search.ndltd.org/etd/marshall/oai:mds.marshall.edu:etd-2773","repository":{"repo_id":"marshall","name":"Marshall University","base_url":"https://mds.marshall.edu/do/oai/"},"display":{"title":"Pharmacology of disulfiram as an antibacterial agent","abstract":"Disulfiram (Antabuse®) is an oral prescription drug used to treat alcohol abuse disorder (AUD). Disulfiram (DSF) and its metabolites act on the body by inhibiting multiple enzymes involved in alcohol metabolism. This study aims to understand the pharmacology of disulfiram as an antibacterial medication. Previous studies on DSF showed antibiotic activity against multidrug-resistant Staphylococcus aureus strains (MRSA). The initial aim of this study was to decipher the mechanisms involved in inhibiting bacterial growth by DSF, which was done by performing biochemical studies. The studies revealed that DSF had antagonistic effects on redox buffering and energy production. Another aim of this study was to evaluate the in vitro pharmacodynamics of DSF in combination with vancomycin (VAN) against S. aureus strains with intermediate levels of susceptibility. The data showed that DSF had synergistic potential with VAN, significantly antagonizing the growth of S. aureus when combined. Overall, this study established that DSF has significant antibacterial activity against S. aureus individually. Moreover, it could be used as an antibiotic adjuvant with VAN against several S. aureus strains with intermediate levels of VAN susceptibility.","abstract_html":"Disulfiram (Antabuse®) is an oral prescription drug used to treat alcohol abuse disorder (AUD). Disulfiram (DSF) and its metabolites act on the body by inhibiting multiple enzymes involved in alcohol metabolism. This study aims to understand the pharmacology of disulfiram as an antibacterial medication. Previous studies on DSF showed antibiotic activity against multidrug-resistant Staphylococcus aureus strains (MRSA). The initial aim of this study was to decipher the mechanisms involved in inhibiting bacterial growth by DSF, which was done by performing biochemical studies. The studies revealed that DSF had antagonistic effects on redox buffering and energy production. Another aim of this study was to evaluate the in vitro pharmacodynamics of DSF in combination with vancomycin (VAN) against S. aureus strains with intermediate levels of susceptibility. The data showed that DSF had synergistic potential with VAN, significantly antagonizing the growth of S. aureus when combined. Overall, this study established that DSF has significant antibacterial activity against S. aureus individually. Moreover, it could be used as an antibiotic adjuvant with VAN against several S. aureus strains with intermediate levels of VAN susceptibility.","abstract_has_math":false,"creators":["Meka, Yogesh"],"institution":null,"degree_name":"Pharmaceutical Sciences","degree_level":"Thesis","degree_discipline":"School of Pharmacy","degree_department":null,"school":null,"contributors":["Dr. Timothy Long, Committee Chairperson","Dr. Jeremy McAleer, Committee Member","Dr. Michael Hambuchen, Committee Member"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-21T19:58:01Z","subjects":["Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://mds.marshall.edu/etd/1768","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://mds.marshall.edu/etd/1768","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://mds.marshall.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Amds.marshall.edu%3Aetd-2773","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Dr. Timothy Long, Committee Chairperson","Dr. Jeremy McAleer, Committee Member","Dr. Michael Hambuchen, Committee Member"]},{"key":"dc:creator","label":"Author","values":["Meka, Yogesh"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2023-05-02T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2023-01-01T08:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["School of Pharmacy"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Pharmaceutical Sciences"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://mds.marshall.edu/etd/1768"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Disulfiram (Antabuse®) is an oral prescription drug used to treat alcohol abuse disorder (AUD). Disulfiram (DSF) and its metabolites act on the body by inhibiting multiple enzymes involved in alcohol metabolism. This study aims to understand the pharmacology of disulfiram as an antibacterial medication. Previous studies on DSF showed antibiotic activity against multidrug-resistant Staphylococcus aureus strains (MRSA). The initial aim of this study was to decipher the mechanisms involved in inhibiting bacterial growth by DSF, which was done by performing biochemical studies. The studies revealed that DSF had antagonistic effects on redox buffering and energy production. Another aim of this study was to evaluate the in vitro pharmacodynamics of DSF in combination with vancomycin (VAN) against S. aureus strains with intermediate levels of susceptibility. The data showed that DSF had synergistic potential with VAN, significantly antagonizing the growth of S. aureus when combined. Overall, this study established that DSF has significant antibacterial activity against S. aureus individually. Moreover, it could be used as an antibiotic adjuvant with VAN against several S. aureus strains with intermediate levels of VAN susceptibility."]},{"key":"dc:title","label":"Title","values":["Pharmacology of disulfiram as an antibacterial agent"]}]}],"canonical_facts":{"dc:contributor":["Dr. Timothy Long, Committee Chairperson","Dr. Jeremy McAleer, Committee Member","Dr. Michael Hambuchen, Committee Member"],"dc:creator":["Meka, Yogesh"],"dc:date.available":["2023-05-02T07:00:00Z"],"dc:date.created":["2023-01-01T08:00:00Z"],"dc:description.abstract":["Disulfiram (Antabuse®) is an oral prescription drug used to treat alcohol abuse disorder (AUD). Disulfiram (DSF) and its metabolites act on the body by inhibiting multiple enzymes involved in alcohol metabolism. This study aims to understand the pharmacology of disulfiram as an antibacterial medication. Previous studies on DSF showed antibiotic activity against multidrug-resistant Staphylococcus aureus strains (MRSA). The initial aim of this study was to decipher the mechanisms involved in inhibiting bacterial growth by DSF, which was done by performing biochemical studies. The studies revealed that DSF had antagonistic effects on redox buffering and energy production. Another aim of this study was to evaluate the in vitro pharmacodynamics of DSF in combination with vancomycin (VAN) against S. aureus strains with intermediate levels of susceptibility. The data showed that DSF had synergistic potential with VAN, significantly antagonizing the growth of S. aureus when combined. Overall, this study established that DSF has significant antibacterial activity against S. aureus individually. Moreover, it could be used as an antibiotic adjuvant with VAN against several S. aureus strains with intermediate levels of VAN susceptibility."],"dc:identifier":["https://mds.marshall.edu/etd/1768"],"dc:subject":["Medicine and Health Sciences","Pharmaceutics and Drug Design","Pharmacy and Pharmaceutical Sciences"],"dc:title":["Pharmacology of disulfiram as an antibacterial agent"],"thesis:degree_discipline":["School of Pharmacy"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Pharmaceutical Sciences"]},"updated_at":"2026-11-21T19:58:01Z"}